Revelation Biosciences Corp (REVB) - Long-Term Debt to Capital Coefficient

Revelation Biosciences develops immunotherapy agents where formula approval will ensure massive margins alongside low raw material costs. This market trend visualized in monetary format on GURU.Markets shows a value of 0.05. The business delegates testing to external contractors while maintaining full control over patents. Additionally, Revelation Biosciences is developing scientific alliances with universities to stimulate natural human immunity.

This ratio determines the extent of the company's dependence on long-term debt financing relative to its equity. By analyzing the long-term debt-to-equity ratio on the GURU.Markets platform, an investor assesses the issuer's long-term solvency. The metric is calculated as the ratio of liabilities with a maturity of more than one year to the net asset value. For Revelation Biosciences (REVB), this balance is critical, as a high scientific reputation in immunology allows the company to attract capital on favorable terms. Low values here confirm financial stability during a period of active growth in business authority.